No Data
Form 144 | Denali Therapeutics(DNLI.US) Director Proposes to Sell 143.04K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Denali Therapeutics(DNLI.US)$ Director VICKI LEE SATO intends to sell 6,160 shares of its common stock on Jul 1, with a total market value of approximately $143.04K.
Form 144 | Denali Therapeutics(DNLI.US) Director Proposes to Sell 696.6K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Denali Therapeutics(DNLI.US)$ Director STEVE KROGNES intends to sell 30,000 shares of its common stock on Jul 1, with a total market value of approximately $696.6K.
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
Denali Therapeutics (DNLI) Moves 5.8% Higher: Will This Strength Last?
ALS Therapy Market Seen Increasing to Nearly $1.3B by 2029
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Flagship Pioneering and ProFound Therapeutics, a Flagship-founded company pioneering the expanded human proteome to develop novel medicines for a...